The Glasgow Microenvironment Score associates with prognosis and adjuvant chemotherapy response in colorectal cancer

The Glasgow Microenvironment Score (GMS) combines peritumoural inflammation and tumour stroma percentage to assess interactions between tumour and microenvironment. This was previously demonstrated to associate with colorectal cancer (CRC) prognosis, and now requires validation and assessment of int...

Full description

Saved in:
Bibliographic Details
Published in:British journal of cancer 2021-02, Vol.124 (4), p.786-796
Main Authors: Alexander, Peter G, Roseweir, Antonia K, Pennel, Kathryn A F, van Wyk, Hester C, Powell, Arfon G M T, McMillan, Donald C, Horgan, Paul G, Kelly, Caroline, Hay, Jennifer, Sansom, Owen, Harkin, Andrea, Roxburgh, Campbell S D, Graham, Janet, Church, David N, Tomlinson, Ian, Saunders, Mark, Iveson, Tim J, Edwards, Joanne, Park, James H
Format: Article
Language:English
Subjects:
Aged
Antineoplastic Combined Chemotherapy Protocols - administration & dosage
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Cancer
Capecitabine - administration & dosage
Chemotherapy
Chemotherapy, Adjuvant
Cohort Studies
Colorectal cancer
Colorectal carcinoma
Colorectal Neoplasms - drug therapy
Colorectal Neoplasms - pathology
Disease-Free Survival
Female
Fluorouracil - administration & dosage
Humans
Inflammation
Kaplan-Meier Estimate
Leucovorin - administration & dosage
Male
Medical prognosis
Microenvironments
Middle Aged
Neoplasm Staging
Organoplatinum Compounds - administration & dosage
Oxaliplatin - administration & dosage
Prognosis
Reproducibility of Results
Stroma
Survival
Tumor Microenvironment
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The Glasgow Microenvironment Score (GMS) combines peritumoural inflammation and tumour stroma percentage to assess interactions between tumour and microenvironment. This was previously demonstrated to associate with colorectal cancer (CRC) prognosis, and now requires validation and assessment of interactions with adjuvant therapy. Two cohorts were utilised; 862 TNM I-III CRC validation cohort, and 2912 TNM II-III CRC adjuvant chemotherapy cohort (TransSCOT). Primary endpoints were disease-free survival (DFS) and relapse-free survival (RFS). Exploratory endpoint was adjuvant chemotherapy interaction. GMS independently associated with DFS (p = 0.001) and RFS (p 
ISSN:0007-0920
1532-1827
DOI:10.1038/s41416-020-01168-x